

Special Issue

Triple Negative Breast Cancer: From Biology to Treatment

Message from the Guest Editor

Among breast cancer subtypes, triple negative is the less common and the most challenging to manage due to few treatment options and a worse prognosis compared to luminal and HER2-positive disease. In particular, neoadjuvant chemotherapy represents, at this point, the cornerstone of treatment of early stage in clinical practice, and the addition of immune checkpoint inhibitors targeting PD-L1 to chemotherapy has become the standard of care in first line for PD-L1 positive disease. Translational and clinical research are now focusing on almost all aspects concerning triple negative breast cancer: the molecular characterization, the biological and clinical peculiarity of BRCA-associated cases, the role of immunotherapy in early-stage disease and of new antibody–drug conjugates in an advanced setting. This Special Issue will highlight the current state of the art about triple negative breast cancer, moving from its biology to management in every setting of disease, and will explore future perspectives in terms of diagnosis, role of prognostic and predictive biomarkers, and therapeutic options potentially entering the next landscape of treatment.

Guest Editor

Dr. Lucia Del Mastro

UO Breast Unit, University of Genova - IRCCS Ospedale Policlinico San Martino, 10 - 16132 Genova, Italy

Deadline for manuscript submissions

closed (15 October 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/85957

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)